Our Values
Message
Corporate Philosophy
Sawai at a Glance
Transparency
Products
Quality Policy & Feature of Each Function
ESG Data（Related Content）New Window
Sustainability
Sustainability Initiatives
Our Approach
Integrated Report（Related Content）New Window
Our Humanistic Business
Corporate Profile
Corporate History
InvestorsNew Window
Feb. 15. 2018
Sawai Pharmaceutical receives approvals for 8 compounds with 19 strengths of generic drugs
Feb. 13. 2018
IR "Summary of Financial Results for the 3rd Quarter of FY2017"
IR "Financial Results for the 3rd Quarter of FY2017"
Nov. 13. 2017
Sawai Pharmaceutical Forms Strategic Alliance with Sumitomo Corp in the US Generics Market
IR "Summary of Financial Results for the 1st Half of FY2017"
IR "Financial Results for the 1st Half of FY 2017"
Aug. 14. 2017
IR "Summary of Financial Results for the 1st Quarter of FY2017"
IR "Financial Results for the 1st Quarter of FY2017"
Jun. 01. 2017
Sawai Pharmaceutical Completes Acquisition of Upsher-Smith Laboratories’ Generics Business
May. 15. 2017
IR “Summary of Financial Results for FY2016”
IR "Financial Results for FY2016"
Apr. 20. 2017
Japan’s Sawai Pharmaceutical to Acquire the Generics Business of U.S. Upsher-Smith Laboratories
Feb. 10. 2017
IR "Summary of Financial Results for the 3rd Quarter of FY2016"
IR "Financial Results for the 3rd Quarter of FY2016"
